Study of STYLAGE® XXL for Volume Deficiency in the Mid-Face

NCT05355454 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-09-10

No results posted yet for this study

Summary

The primary objective of the study is to demonstrate the superiority of STYLAGE® XXL versus no treatment at 24 weeks after baseline for the creation or restoration of volume deficit in the mid-face.

Conditions

  • Volume Deficiency in the Mid-Face
  • Aging
  • Aesthetics

Interventions

DEVICE

STYLAGE® XXL

Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face. Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face. Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face.

DEVICE

STYLAGE® XXL

Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face. Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face. Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face.

Sponsors & Collaborators

  • Avania B.V.

    collaborator UNKNOWN
  • Canfield Scientific Inc.

    collaborator UNKNOWN
  • Laboratoires Vivacy

    lead INDUSTRY

Principal Investigators

  • Hervé RASPALDO, MD · Private Clinic, GENEVA, SWITZERLAND

  • Hugues CARTIER, MD · Centre Medical Saint-Jean, ARRAS, FRANCE

  • Thomas RAPPL, MD · Medical Aesthetic Research Academy, GRAZ, AUSTRIA

  • Cyril CLERICO, MD · Private Practice, NICE, FRANCE

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-06
Primary Completion
2024-05-15
Completion
2025-04-25

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05355454 on ClinicalTrials.gov